Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $5.1000 (-4.49%) ($5.1000 - $5.1000) on Wed. May. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.29% (three month average) | RSI | 54 | Latest Price | $5.1000(-4.49%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2.3% a day on average for past five trading days. | Weekly Trend | ADAP advances 6% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XAR(95%) UNG(64%) XLC(48%) SIL(93%) SLV(51%) | Factors Impacting ADAP price | ADAP will decline at least -2.145% in a week (0% probabilities). IWD(23%) LIT(-1%) IYT(20%) XRT(33%) IBB(76%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.145% (StdDev 4.29%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.25 | 5 Day Moving Average | $5.51(-7.44%) | 10 Day Moving Average | $5.51(-7.44%) | 20 Day Moving Average | $5.25(-2.86%) | To recent high | -25.4% | To recent low | 1.5% | Market Cap | $789m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |